(3S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

We are (3S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid CAS:103733-66-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: (3S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
CAS.NO: 103733-66-0
Synonyms:
3-ISOQUINOLINECARBOXYLIC ACID,1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-,(3S)
6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-3(S)-Carboxylic Acid
(S)-1,2,3,4-Tetrahydro-6,7-dimethoxyisoquinoline-3-carboxylic acid
(s)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

Molecular Formula:C12H16ClNO4
Molecular Weight:273.71300

Physical and Chemical Properties:
Density: 1.232 g / cm3
Boiling point: 434.8ºC at 760 mmHg
Melting point: 278-279 ° C
Flash point: 216.7ºC
Refractive index: /

Specification:
Appearance: White or off-white powder
Purity:≥99%
Moisture Content:≤1.0%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Moexipril CAS:103775-10-6

Related News: Inceptua Medicines Access is a business unit of the Inceptua Group. It offers full access solutions for the design, implementation and delivery of Pre-approval and Medicines Access Programs on behalf of biopharmaceutical companies.2-Fluoro-5-(trifluoromethyl)pyridine CAS:69045-82-5 Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: “Within the top 20 global companies that spent the most on R&D in 2018, the top spender – despite having the second smallest annual revenue of the group at $15.28 billion – is Celgene, whose R&D spend was equal to 37% of its annual revenue.2-nitro-3-piridinamina CAS:13269-19-7 Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: “Within the top 20 global companies that spent the most on R&D in 2018, the top spender – despite having the second smallest annual revenue of the group at $15.28 billion – is Celgene, whose R&D spend was equal to 37% of its annual revenue.165047-23-4 In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum.Under the high pressure of environmental protection, if Chinese API companies want to achieve sustainable operation, they must recognize the current situation, increase environmental investment, and carry out industrial upgrades, focusing on new product development, process improvement, CMO business and new technology research. And other businesses to carry out work to improve safety, environmental protection, quality, cost and other capabilities, so as to seize structural opportunities.